Array ( [1611403992] => Array ( [wordfence_hourly_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1611405573] => Array ( [wp_privacy_delete_old_export_files] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1611406081] => Array ( [wpm_update_stats] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => hourly [args] => Array ( ) [interval] => 3600 ) ) ) [1611408726] => Array ( [wp_update_themes] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) [wp_update_plugins] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1611409474] => Array ( [wp_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611412153] => Array ( [wp_version_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1611415073] => Array ( [wp_session_garbage_collection] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => twicedaily [args] => Array ( ) [interval] => 43200 ) ) ) [1611418024] => Array ( [akismet_scheduled_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611421011] => Array ( [yoast_tracking] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611438061] => Array ( [wpseo_permalink_structure_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) [wpseo_home_url_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611438074] => Array ( [wpseo-reindex] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611469485] => Array ( [recovery_mode_clean_expired_keys] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611472112] => Array ( [ai1wm_storage_cleanup] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611478171] => Array ( [wp_scheduled_auto_draft_delete] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611483311] => Array ( [delete_expired_transients] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611483352] => Array ( [wpseo-reindex-links] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611484014] => Array ( [wordfence_daily_cron] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => daily [args] => Array ( ) [interval] => 86400 ) ) ) [1611496200] => Array ( [wordfence_start_scheduled_scan] => Array ( [afad825ab071aef2728c7c04da62fda2] => Array ( [schedule] => [args] => Array ( [0] => 1611496200 ) ) ) ) [1611728690] => Array ( [wp_site_health_scheduled_check] => Array ( [40cd750bba9870f18aada2478b24840a] => Array ( [schedule] => weekly [args] => Array ( ) [interval] => 604800 ) ) ) [1611755400] => Array ( [wordfence_start_scheduled_scan] => Array ( [107e7d3e78442fe8efdb48fdb9e94dbb] => Array ( [schedule] => [args] => Array ( [0] => 1611755400 ) ) ) ) )
Etiquetas: 2007, Acerca de los anticuerpos monoclonales, Amgen Oncología, Análisis de KRAS, Barcelona, Cáncer Colorrecta, Células neoplásicas malignas, Colon, Cribado, EGFR, Enfermedad, Estudio pivotal de panitumumab, Factores de riesgo, Folleto informativo, Folleto informativo del K-RAS, Función de los tratamientos selectivos para el EGFR, GI, Hitos en la historia del EGFR, Indicación de panitumumab, Información europea importante sobre la seguridad del producto, Juan Carlos Esteban, Panitumumab, Prevención del crecimiento de las células cancerígenas, Proteina, Protooncogenes RAS, Receptor del factor de crecimiento epidérmico, Recto, Resultados del ensayo clínico, salud, Sanidad, Síntomas y signos, Sistema digestivo, Sistema gastrointestinal, Técnica del Xenomouse, ¿Cómo actúa el KRAS?, ¿Cómo se está estudiando KRAS en el tratamiento del cáncer?, ¿Qué es KRAS?, ¿Qué es panitumumab?, ¿Qué tipos de cáncer están relacionados con KRAS?.